Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorYasar, H. Arzu
dc.contributor.authorTurna, Hande
dc.contributor.authorEsin, Ece
dc.contributor.authorSedef, A. Murat
dc.contributor.authorAlkan, Ali
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorOzdemir, Nuriye
dc.contributor.authorSendur, M. A. Nahit
dc.contributor.authorSezer, Ahmet
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorUtkan, Gungor
dc.contributor.authorAkbulut, Hakan
dc.contributor.authorCelik, Ismail
dc.contributor.authorAbali, Huseyin
dc.contributor.authorUrun, Yuksel
dc.date.accessioned2025-10-16T15:21:50Z
dc.date.issued2020
dc.identifier.doi10.1177/1078155219840796
dc.identifier.otherWOS:000513263200002
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/7737
dc.publisherSAGE PUBLICATIONS LTD
dc.sourceJOURNAL OF ONCOLOGY PHARMACY PRACTICE
dc.subjectIpilimumab
dc.subjectuveal melanoma
dc.subjectmucosal melanoma
dc.subjectprognostic factors
dc.titlePrognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS